Latest News and Press Releases

EXTON, PA, May 01, 2025 (GLOBE NEWSWIRE) -- Patients with sickle cell disease (SCD) continue to face severe complications, despite advances in treatment that have helped mitigate some risks....

Agios Pharmaceuticals, Inc. today reported business highlights and financial results for the first quarter ended March 31, 2025.

COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT UN AVIS D'ACCEPTATION POUR LE BREVET AMERICAIN COUVRANT JUSQU'EN 2040 LE MASITINIB DANS LE TRAITEMENT DE LA DREPANOCYTOSE Paris, 14 avril 2025, 18h ...

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE Paris, April 14, 2025, 6pm CET AB Science SA...

DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a...

Dublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Sickle Cell Anemia Testing and Screening Market by Technology, by Age Group, End-User, and By Region" report has been added to ...

- Phase 1 study and Investigator Initiated Trial evaluating KL003 for patients with beta thalassemia demonstrated an encouraging efficacy signal and favorable safety profile – - Manufacturing costs...

Mexico, Mexico City, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Introspective Market Research has published a comprehensive report on the Global Sickle Cell Disease (SCD) Market, highlighting an expected...

COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT UN AVIS D'ACCEPTATION POUR LE BREVET EUROPÉEN COUVRANT JUSQU'EN 2040 LE MASITINIB DANS LE TRAITEMENT DE LA DREPANOCYTOSE CETTE DÉCISION...

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE THIS DECISION FURTHER STRENGTHENS...